Sartorius Stedim Biotech S.A. (SDMHF) Stock

About Sartorius Stedim Biotech S.A.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Sartorius Stedim Biotech S.A. is headquartered in FR.

Sartorius Stedim Biotech S.A. (SDMHF) stock trades at $244.00 with a market capitalization of $23.74B. The stock is valued at a price-to-earnings (P/E) ratio of 72.45, price-to-book of 5.02, price-to-sales of 7.08. Over the past 52 weeks the stock has ranged between $178.30 and $264.30, and currently trades 7.7% below its 52-week high. It pays a dividend yielding 0.33%.

On profitability, Sartorius Stedim Biotech S.A. generates a return on equity (ROE) of 7.11%, return on capital employed of 8.63%, an operating margin of 19.38%, a net profit margin of 9.74%.

In its most recent fiscal year, Sartorius Stedim Biotech S.A. reported annual revenue of $3.0B, net profit of $266.0M, revenue has compounded at 9.2% a year over the last five years, profit at -4.6% a year.

The balance sheet shows a debt-to-equity ratio of 0.57, a current ratio of 1.16, total assets of $8.0B, $426.0M in cash and equivalents.

SDMHF has an average daily trading volume of 1,250 shares, a beta of 1.15.

Official website: www.sartorius.com